TS-004716 — This scanning system uses a microchip to capture the required DSCSA elements from each medication, improving the order process for both pharmaceutical wholesale distributors and pharmacies.

TS-004715 — Instead of manually filling out pharmaceutical order forms, this new eCommerce platform allows users to do it electronically.

TS-004714 — This eCommerce platform creates a standardized approach to the pharmaceutical procurement process for pharmacy purchasing personnel.

TS-004712 — Made with CRISPR-CAS9 genome editing technology, this mouse model tests if certain human variants cause craniofacial conditions.

TS-004711 — This IP is a self-contained, handheld box with a colorful LCD display and programmable microcontroller that explores magnetic fields typically found in an MRI room.

TS-004710 — This XGBoost Machine Learning classifier predicts whether a baby admitted to a level IV NICU will require genetic medicine services in the first 18 months of life.

TS-004709 — To improve the accuracy of mental health diagnosis, this online toolkit will provide an evidence-based assessment for patients, clinicians and providers.

TS-004708 — In post-solid organ and bone marrow transplants, an at-home device will measure drug levels to help health facilities and patients save time and money.

TS-004707 — This IP is a gene therapy designed to treat cystic fybrosis using variants to improve stability and channel conductivity.

TS-004706 — Based on delayed co-detection, this software detects space-time profiles through a data-driven approach.

TS-004705 — Modified GNPs offer a promising avenue for therapeutic interventions in the field of rare neurological disorders, providing insights into their effectiveness at the cellular level and offering potential avenues for clinical applications.

TS-004704 — This IP automates the miniaturization of large gene targets through a structure-based protein engineering AI algorithm.

TS-004703 — For AAVs that harbor gene knockdown machinery, this IP is a novel potency assay development for release testing that creates a HEK293T stable cell line to integrate two genetic components.

TS-004619 — A medical device to assess tissue stiffness in the brain, particularly in epileptogenic brain tissue.

TS-004618 — A reusable silicone model that utilizes temperature responsive pigments to mimic tissue reactions to heat. This model can be used in medical training simulations of procedures that involve heat, such as laser ablation therapy.

TS-004616 — A method for targeted delivery and constitutive expression of large genes using adeno-associated viral (AAVs) vectors that contain ubiquitous mini-promoters. Incorporation of the compact mini-promoters will increase the cargo space of the AAVs such that larger genes can be packaged into the vectors.

TS-004612 — This IP is a therapeutic strategy for facioscapulohumeral dystrophy (FSHD), which is associated with an inappropriate expression of DUX4. Using dual AAV split-intein vectors, it expresses full-length SMCHD1, enhances epigenetic silencing and reduces DUX4 toxicity.

TS-004611 — This software tool annotates burns in existing medical records to accurately estimate %TBSA-burned and minimize errors from inaccurate annotations or miscalcualtions. This is acheived through mapping 2D images onto a body-accurate 3D geometry.

TS-004610 — This is a new approach to gene therapies in cells that are longer than 4.5 kb. By inhibiting DNA-PKcs and 53BP1, it allows the enrichment cassette in the second AAV to be replaced with genetic cargo, which consequently allows insertion for genes up to 6.5-7 kb.

TS-004608 —

TS-004607 — Using CRISPR/Cas9 genome editing can eliminate an inhibitory checkpoint receptor called TIGIT, which improves anti-tumor activity and cellular therapy for cancer. Chimeric antigen receptor technology also introduces an immune activating CAR within the TIGIT gene locus.

TS-004606 — For patients with NF2-related Schwannomatosis, there's currently no FDA-approved treatment drug available. Using Nelfinavir, an existing FDA-approved drug, will efficiently and safely block retroviral protease activity. This anti-retroviral drug reduces the growth of existing tumors and prevents/slows the generation of new tumors.

TS-004605 — The polygenic scores (PGS) browser, a web-based application, improves precision medicine and calculates an individual’s genetic risk, providing access to over 3,000 PGS models and 10,000 studies.

TS-004604 — The polygenic scores (PGS) browser is a web-based application designed to improve precision medicine and calculate an individual’s genetic risk. The application provides users with access to a comprehensive and well-annotated database with over 3,000 PGS models. Users may select the most suita…

TS-004603 — In the case of mass casualty events, unidentified patients will be given an AirTag, which will track the patient’s location and allow the tracker to receive identifying patient details upon arrival to the hospital.

TS-004602 — This mnemonic device condenses and standardizes clinical research processes by organizing responsibilities into five critical steps. Each task follows a consistent format found in the compact and portable reference guide.

TS-004601 — A medical device used to detect a leak in an ostomy pouch and alert the user of the leak. This device would be implantable/ attached to the ostomy pouch and detect leaks via the presence of oxygen. Upon detection of the leak, the device would emit an alarm, or notify the user through their mobile phone such that they can replace the pouch in a timely manner.

TS-004600 — A device to mount simulation vitals tablets over monitors in actual patient rooms for use in in situ simulations.

TS-004598 — This system may help improve the safety of AAV vector products by decreasing cross-packaged bacterial sequences, increasing correctly packaged AAV payloads and blunting ITR-driven transcription of cross-packaged material to avoid expressing potentially toxic bacterial sequences.

TS-004596 — There's a signficiant unmet need among thousands of Americans who struggle with genetic neuromuscular disease; this one-time AAV-delivered proprietary engineered miRNA targets core disease biology, specifically in Facioscapulohumeral Muscular Dystrophy (FSHD). This durable gene therapy reduces immunogenicity by taking advantage of nature’s highly active gene regulation biology.